Pfizer Invests Billions in Treatments for Coming ‘Heart Failure Pandemic’

Pfizer is investing billions of dollars in treatments to prepare for a looming “heart failure pandemic.”

The Covid mRNA vaccine maker is making a big investment in treatment for heart failure as cases of myocarditis and sudden cardiac deaths skyrocket.

The pharmaceutical giant recently acquired several companies. This includes a major $6.7 billion cash acquisition of Arena Pharmaceuticals.

Arena Pharmaceuticals is a firm specializing in developing treatments, particularly for heart inflammation conditions like myocarditis and pericarditis.

Pfizer is now predicted to make tens of billions of dollars in profits from the spike in heart failure.

The company is expecting to capitalize on the huge spike in heart failure as sales of its Covid vaccines have now dried up.

The news comes as scientists are now warning that the latest Covid variant could trigger a “heart failure pandemic.”

Research into the new strain known as JN.1, could cause a “global healthcare risk” related to COVID-19.

Scientists claim this strain of the virus could start a “heart failure pandemic.”

Health experts have warned that there is an increase in the chances of potential heart issues for those who catch the disease.

Due to the influx of a new strain JN.1, there has been a spike in Covid cases in several countries.

Scientists are claiming that new strains are responsible for the spike in deadly heart failure that started in 2021.